These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 16039528)
1. Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation. Ahn JS; Radhakrishnan ML; Mapelli M; Choi S; Tidor B; Cuny GD; Musacchio A; Yeh LA; Kosik KS Chem Biol; 2005 Jul; 12(7):811-23. PubMed ID: 16039528 [TBL] [Abstract][Full Text] [Related]
2. Cdk5 as a drug target for the treatment of Alzheimer's disease. Lau LF; Seymour PA; Sanner MA; Schachter JB J Mol Neurosci; 2002 Dec; 19(3):267-73. PubMed ID: 12540052 [TBL] [Abstract][Full Text] [Related]
3. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? Leclerc S; Garnier M; Hoessel R; Marko D; Bibb JA; Snyder GL; Greengard P; Biernat J; Wu YZ; Mandelkow EM; Eisenbrand G; Meijer L J Biol Chem; 2001 Jan; 276(1):251-60. PubMed ID: 11013232 [TBL] [Abstract][Full Text] [Related]
4. Cleavage of the cyclin-dependent kinase 5 activator p35 to p25 does not induce tau hyperphosphorylation. Kerokoski P; Suuronen T; Salminen A; Soininen H; Pirttilä T Biochem Biophys Res Commun; 2002 Nov; 298(5):693-8. PubMed ID: 12419309 [TBL] [Abstract][Full Text] [Related]
5. A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal Cdk5 activator. Chou KC; Watenpaugh KD; Heinrikson RL Biochem Biophys Res Commun; 1999 Jun; 259(2):420-8. PubMed ID: 10362524 [TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of human tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key participants. Flaherty DB; Soria JP; Tomasiewicz HG; Wood JG J Neurosci Res; 2000 Nov; 62(3):463-72. PubMed ID: 11054815 [TBL] [Abstract][Full Text] [Related]
7. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Leost M; Schultz C; Link A; Wu YZ; Biernat J; Mandelkow EM; Bibb JA; Snyder GL; Greengard P; Zaharevitz DW; Gussio R; Senderowicz AM; Sausville EA; Kunick C; Meijer L Eur J Biochem; 2000 Oct; 267(19):5983-94. PubMed ID: 10998059 [TBL] [Abstract][Full Text] [Related]
8. New approaches to the discovery of cdk5 inhibitors. Glicksman MA; Cuny GD; Liu M; Dobson B; Auerbach K; Stein RL; Kosik KS Curr Alzheimer Res; 2007 Dec; 4(5):547-9. PubMed ID: 18220519 [TBL] [Abstract][Full Text] [Related]
9. Development of an assay to screen for inhibitors of tau phosphorylation by cdk5. Ahn JS; Musacchio A; Mapelli M; Ni J; Scinto L; Stein R; Kosik KS; Yeh LA J Biomol Screen; 2004 Mar; 9(2):122-31. PubMed ID: 15006135 [TBL] [Abstract][Full Text] [Related]
10. Mitotic-like tau phosphorylation by p25-Cdk5 kinase complex. Hamdane M; Sambo AV; Delobel P; Bégard S; Violleau A; Delacourte A; Bertrand P; Benavides J; Buée L J Biol Chem; 2003 Sep; 278(36):34026-34. PubMed ID: 12826674 [TBL] [Abstract][Full Text] [Related]
11. p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro. Town T; Zolton J; Shaffner R; Schnell B; Crescentini R; Wu Y; Zeng J; DelleDonne A; Obregon D; Tan J; Mullan M J Neurosci Res; 2002 Aug; 69(3):362-72. PubMed ID: 12125077 [TBL] [Abstract][Full Text] [Related]
12. Evidence for cdk5 as a major activity phosphorylating tau protein in porcine brain extract. Hosoi T; Uchiyama M; Okumura E; Saito T; Ishiguro K; Uchida T; Okuyama A; Kishimoto T; Hisanaga S J Biochem; 1995 Apr; 117(4):741-9. PubMed ID: 7592534 [TBL] [Abstract][Full Text] [Related]
13. A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons. Zheng YL; Kesavapany S; Gravell M; Hamilton RS; Schubert M; Amin N; Albers W; Grant P; Pant HC EMBO J; 2005 Jan; 24(1):209-20. PubMed ID: 15592431 [TBL] [Abstract][Full Text] [Related]
14. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Patrick GN; Zukerberg L; Nikolic M; de la Monte S; Dikkes P; Tsai LH Nature; 1999 Dec; 402(6762):615-22. PubMed ID: 10604467 [TBL] [Abstract][Full Text] [Related]
15. The levels of cdk5 and p35 proteins and tau phosphorylation are reduced during neuronal apoptosis. Kerokoski P; Suuronen T; Salminen A; Soininen H; Pirttilä T Biochem Biophys Res Commun; 2001 Feb; 280(4):998-1002. PubMed ID: 11162625 [TBL] [Abstract][Full Text] [Related]
16. Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening. Chatterjee A; Cutler SJ; Doerksen RJ; Khan IA; Williamson JS Bioorg Med Chem; 2014 Nov; 22(22):6409-21. PubMed ID: 25438765 [TBL] [Abstract][Full Text] [Related]
17. Colocalization and fluorescence resonance energy transfer between cdk5 and AT8 suggests a close association in pre-neurofibrillary tangles and neurofibrillary tangles. Augustinack JC; Sanders JL; Tsai LH; Hyman BT J Neuropathol Exp Neurol; 2002 Jun; 61(6):557-64. PubMed ID: 12071639 [TBL] [Abstract][Full Text] [Related]
18. Effects of cyclin-dependent kinase-5 activity on apoptosis and tau phosphorylation in immortalized mouse brain cortical cells. Shelton SB; Krishnamurthy P; Johnson GV J Neurosci Res; 2004 Apr; 76(1):110-20. PubMed ID: 15048935 [TBL] [Abstract][Full Text] [Related]
19. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. Mettey Y; Gompel M; Thomas V; Garnier M; Leost M; Ceballos-Picot I; Noble M; Endicott J; Vierfond JM; Meijer L J Med Chem; 2003 Jan; 46(2):222-36. PubMed ID: 12519061 [TBL] [Abstract][Full Text] [Related]
20. Probing novel 1-aza-9-oxafluorenes as selective GSK-3beta inhibitors. Voigt B; Krug M; Schächtele C; Totzke F; Hilgeroth A ChemMedChem; 2008 Jan; 3(1):120-6. PubMed ID: 18000938 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]